ReviewMolecular neurobiology2025
Beyond mTOR: Unraveling the Complex Pathophysiology and Signaling Pathways in Focal Cortical Dysplasia.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhanced brain delivery of oleanolic acid by GSH-PEGylated liposomes and its amelioration of scopolamine-induced cognitive dysfunction via multi-target regulation.International journal of pharmaceutics: X · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Focal cortical dysplasia (FCD) is a common cause of drug-resistant epilepsy, characterized by abnormal cortical development and disrupted neuronal connectivity. The pathogenesis of FCD involves complex molecular mechanisms, among which the mTOR (mechanistic target of rapamycin) pathway has been extensively studied. Despite its well-established role in cellular growth and neurodevelopment, mTOR signaling does not fully explain the diverse clinical manifestations of FCD. This is evident in the resistance to mTOR inhibitors, which, although effective in some cases, fail to address the cognitive and behavioral deficits associated with the disorder. The limitations of mTOR-based therapies suggest that other signaling pathways and molecular factors may contribute to the pathophysiology of FCD. In this review, we innovatively conceptualize FCD as a spatiotemporally specific signaling disorder, with lesion formation resulting from the imbalance of multiple pathways interacting in distinct cell types. While mTOR is pivotal, its pathological effects are modulated and amplified by a network of signaling cascades, leading to subtype-specific pathway combinations in lesions. This mechanistic framework explains the clinical and histological heterogeneity of FCD and suggests that future studies should validate the causal relationships of specific pathways while exploring multi-target strategies beyond mTOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.